HMGCR and ankylosing spondylitis: Our study did not provide direct evidence indicative of risk reduction in ankylosing spondylitis from statin use, and results of this study along with previous findings only suggested that the HMG-CoA reductase mediated pathway is implicated in the pathogenesis of ankylosing spondylitis and that HMG-CoA reductase could be a possible drug target for the prevention and treatment of ankylosing spondylitis.